What does peptide intact mass analysis confirm, and what does the window exclude?
Peptide intact mass analysis begins with a calculated mass. The sequence, terminal groups, intended modifications and cysteine state are written down, and a monoisotopic mass is calculated for resolved spectra. Where the envelope is unresolved, an average mass is calculated instead, and the certificate must say which type was used. Electrospray ions are collected over a stated charge-state range, deconvoluted, and compared with that calculation. The window, in parts per million or daltons, and the calibrant belong in the same record as the delta. A pass supports one sentence only: under the desalting and source conditions used, the dominant series is consistent with the declared elemental composition.
That sentence does not assign residue order. Leucine and isoleucine share a residue mass, and a composition-preserving dipeptide swap can also hide. Sodium or potassium adducts, and residual trifluoroacetate or acetate, must be assigned before the delta is accepted. Methionine oxidation is a +16 Da related species and should be tabulated, not folded into the identity mass. Deamidation, about +1 Da, can sit inside a loose window on a long chain. Each closed disulfide differs from the reduced thiols by about 2 Da, so the reduction state belongs in the calculation.
Preparation changes the spectrum. Desalting, spray-solvent composition, the acid modifier and source voltage alter adduct survival and in-source fragmentation. In-source fragments misread as extra components will spoil an identity call even when the molecular ion is correct. A complete intact-mass block lists calculated mass, mass type, observed mass, delta, window, charge states, calibrant, and the claims left untested: order, isobaric substitutions and site localisation.
What does peptide mapping test that an intact mass leaves open?
Peptide mapping moves the evidence from one molecular mass to a set of cleavage products. A named enzyme or chemical cleavage is applied, conditions and quench are recorded, and product masses are matched to peptides predicted from the declared sequence. Where the claim includes residue order or a modification site, tandem spectra are required. Fragment ions must cover the bonds the intact mass could not resolve. Coverage is residues or bonds observed, divided by the bonds in the claim, not a remark that the map looked consistent.
Identifying the major phosphorylation domain of murine mdr1b P-glycoprotein required analysis of protein kinase A and protein kinase C phosphorylation sites, a peptide-level question rather than a single intact mass (PMID:7901220). An intact shift might show that phosphate mass is present. It does not show which site inside a domain carries it. A synthetic peptide with a claimed acylation site, disulfide pair or single-residue substitution can share an intact mass across several arrangements; only cleavage or fragment evidence places the change.
Mapping fails in ways an intact-mass pass will not detect. Missed cleavages leave regions unseen. Non-specific cleavage creates extra masses that resemble impurities. Infusion without separation can suppress a deletion peptide that reversed-phase retention would have shown. Keratin and enzyme autolysis ions must not be forced onto the sample sequence. For a very short peptide, targeted tandem spectra of the intact ion can be more specific than a digest that yields pieces too small to retain. The certificate should list expected peptides that were absent. A missing C-terminal peptide means the terminus is not evidenced.
How did published mass-mapping methods keep comparison apart from identification?
Liquid-phase mass mapping is a useful precedent because the comparison claim and the identification claim were not the same experiment. A 2-D liquid separations/mass mapping method was used for interlysate comparison of ovarian cancers (PMID:11985308). Two-dimensional liquid separations-mass mapping was applied to proteins from human cancer cell lysates (PMID:12458006). A published HCT-116 lysate comparison used a 2-D liquid separation mapping method based upon chromatofocusing isoelectric-point fractionation (PMID:12918970). Two-dimensional liquid chromatography protein-expression mapping compared normal and O157:H7 Escherichia coli (PMID:14682054). Each product was a located mass, not a residue-resolved sequence.
Identification was added as a further step. Comprehensive ovarian-cancer proteome work combined liquid-phase separation, mass mapping and tandem mass spectrometry, placing tandem mass spectrometry alongside the map rather than instead of it (PMID:15274142). Identification of metastasis-associated proteins in a human tumour metastasis model used the mass-mapping technique as an identification strategy (PMID:15352249). The laboratory rule to carry across is narrow. An intact mass compares an observation with a calculation or with another lot. A sequence claim, a site claim, or a claim that isobaric sequences have been separated, needs fragment or cleavage evidence stored as its own result. A short synthetic peptide does not need a lysate chromatofocusing gradient. It does need the same wording: a mass-map match is not tandem coverage.
These papers examined complex lysates and are cited for architecture only. They set neither a purity limit nor a mass window for a synthetic peptide, and they are not evidence of any human outcome. Biomarker phrasing in the titles should not be copied onto a lot certificate.
When are intact-mass and peptide-mapping results discordant?
Discordance should be defined before the files are reviewed. If the intact mass lies outside the window while many map peptides match, check calibration, the declared formula, adduct assignment and a modification that shifts every peptide containing one residue. If the intact mass lies inside the window while coverage is incomplete, identity is not confirmed for the uncovered stretch. Isobaric substitutions and a modification sitting on an unobserved peptide both survive a composition match.
Small shifts need local rules, not a wider window. A +1 Da intact difference can be deamidation, a mis-picked monoisotopic peak, or an average-mass calculation error. Mapping separates some of these: deamidation localises to asparagine- or glutamine-containing peptides, whereas a calibration error shifts peptides in one direction across the run. A +16 Da intact shift carried by one methionine peptide supports oxidation at that site. The same intact shift with no mapped carrier stays an unknown. A -18 Da change may reflect dehydration or aspartimide-related chemistry and should be named only when a peptide contains a susceptible motif. Forcing a name onto an unassigned delta is a documentation failure.
Co-elution creates false agreement. An infusion intact-mass measurement can report the major ion and miss a minor related substance. Mapping can then match the major sequence while the impurity never yields a confident peptide. Neither result replaces a chromatographic related-substances measurement with a stated wavelength, reporting threshold and relative retention time. Identity may pass while purity fails. The certificate must be allowed to say both. Collapsing them into one pass/fail line removes the split a receiving laboratory needs.
Which certificate fields stop identity, purity and content being merged?
A research certificate keeps four quantities in separate cells. Chromatographic purity is an area-normalised result at a stated wavelength, integration rule and reporting threshold. Intact mass is the match between observed and calculated mass inside a pre-set window. Peptide mapping, or targeted tandem coverage, is sequence evidence against a coverage rule. Net peptide content, if reported, comes from a quantitative method such as amino-acid analysis or a calibrated chromatographic assay, with any counter-ion or water correction stated. Placing these in a single purity field is a documentation error. Area percent does not confirm a formula. A mass match does not state an impurity level.
Concordance is the Australian procurement control. Product name, sequence string, lot number and analysis date on the intact-mass file must match the mapping file and the chromatographic peak table. Method identifiers should reconstruct the claim: mass-analyser type, monoisotopic or average mass, window, calibrant, enzyme, missed-cleavage limit, and the rule that accepted a fragment. Reviewer sign-off should state which result supports identity and which supports related substances. If mapping was not run, the identity line should read as intact mass only, with sequence order not tested by fragment ions. An unqualified confirmation overstates a composition match.
Raw files are part of the record. A deconvoluted mass without the charge-state spectrum, or a coverage figure without the peptide list, cannot be re-reviewed. File names should be attributable to the lot, integration settings should not be overwritten after sign-off, and a manual peak exclusion needs a recorded reason. These fields describe a research material. They are not a clinical specification, and they do not rank lots by any biological endpoint.
How does peptide intact mass analysis versus peptide mapping guide method selection?
Select the experiment from the ambiguity that remains. For a short unmodified sequence, calibrated intact mass plus chromatographic purity can be proportionate if the certificate states that residue order was not fragment-tested. If a defined leucine/isoleucine order is claimed, intact mass is the wrong final test; a fragment series across that bond is required. A claimed disulfide pattern needs reduced and non-reduced masses, or a disulfide map, because one average mass does not encode pairing. An intact acylation shift shows that the modification mass is present; a fragment or cleavage peptide is what places the site.
Before two suppliers are treated as analytically equivalent, the receiving laboratory should collect a factual method statement. Which mass analyser and resolution were used? Was the mass monoisotopic or average? What window was applied, and was it fixed before review? Which charge states entered deconvolution? Was the sample desalted? If mapping was used, which enzyme, what missed-cleavage limit, what minimum coverage, and which expected peptides were absent? Were unmatched ions above a threshold left as unknowns? Those answers compare lots on method grounds only.
Where a digest adds no orthogonal fact, intact mass with tandem fragmentation of the molecular ion is more specific than a proteomic digest copied onto a pentapeptide. Complex lysates needed fractionation before a mass map was interpretable (PMID:12458006; PMID:12918970). A single synthetic peptide does not need that fractionation, but it needs the same limit on what a mass proves. The mass file and the map file should carry the same lot identifier as the material under test. The comparison is an identity and documentation decision for research material only.
Frequently asked questions
Is peptide intact mass analysis the same as sequence confirmation?
No. Intact-mass analysis tests whether a deconvoluted mass matches a calculated elemental composition inside a stated window. Sequence confirmation requires fragment ions or mapped cleavage peptides that cover the bonds under claim. Leucine/isoleucine order and the site of a modification can remain open after a mass pass. A certificate should say intact mass only when tandem or mapping data were not acquired, rather than using an unqualified identity statement.
Does peptide mapping replace a chromatographic purity result?
No. Mapping asks which parts of a declared sequence were observed as cleavage products or fragment ions. Chromatographic purity asks how much of the ultraviolet peak area, at a stated wavelength and threshold, sits in the main peak versus related substances. A complete map can coexist with a failed purity result if a related substance is present but poorly ionised, or if it was excluded from the search. Keep the two results in separate certificate fields.
Why can two different peptides share one intact mass?
Composition does not encode order. Leucine and isoleucine are isobaric. A swap of two residues that preserves elemental composition preserves the intact mass. Some modification arrangements also share a mass if the modifying group is the same and only the site differs. Peptide mapping or targeted tandem spectra are what separate those cases, and only in the regions actually covered. An uncovered stretch remains untested even when the molecular ion matches.
What should the lot record show if mapping was not performed?
State the calculated mass, whether it is monoisotopic or average, the observed mass, the delta, the window, the calibrant and the charge states used in deconvolution. State that sequence order and modification sites were not tested by fragment ions. Do not leave a blank that a later reader can fill with an unqualified confirmation. Link the file name to the lot number used on the chromatographic report. Absence of mapping is an acceptable design for some short sequences; it is not acceptable to describe that design as full sequence evidence.
Can lysate mass-mapping papers be used as a peptide specification?
No. The cited studies used liquid-phase separation and mass mapping to compare complex lysates, and some added tandem mass spectrometry for identification (PMID:15274142; PMID:11985308; PMID:12918970). They do not supply a purity percentage, a mass window or a coverage threshold for a synthetic research peptide. Use them as architecture: comparison and identification are different claims. Copying biomarker wording from those titles into a certificate would misstate both the papers and the lot.
How should unmatched map ions be reported?
Leave them unmatched if they do not meet the written assignment rule. Name keratin, autolysis or known adducts only when the mass and, where relevant, the fragment pattern support that assignment. Do not force an unmatched ion onto the declared sequence to raise the coverage figure. Record the threshold above which unknowns are listed. An unknown ion is compatible with a passed intact mass; it is a prompt for chromatographic follow-up, not a reason to widen the identity window after the file has been seen.
References
- PMID:15274142 — Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers — Proteomics — 2004
- PMID:12458006 — Two-dimensional liquid separations-mass mapping of proteins from human cancer cell lysates — J Chromatogr B Analyt Technol Biomed Life Sci — 2002
- PMID:11985308 — A 2-D liquid separations/mass mapping method for interlysate comparison of ovarian cancers — Anal Chem — 2002
- PMID:15352249 — Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique — Proteomics — 2004
- PMID:14682054 — Two-dimensional liquid chromatography protein expression mapping for differential proteomic analysis of normal and O157:H7 Escherichia coli — Biotechniques — 2003
- PMID:7901220 — Identification of the major phosphorylation domain of murine mdr1b P-glycoprotein. Analysis of the protein kinase A and protein kinase C phosphorylation sites — J Biol Chem — 1993
- PMID:12918970 — A comparison of drug-treated and untreated HCT-116 human colon adenocarcinoma cells using a 2-D liquid separation mapping method based upon chromatofocusing PI fractionation — Anal Chem — 2003
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
